Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mercy Research
With
Forest Laboratories
Prior to the initiation of Nebivolol and after 10 weeks of Nebivolol therapy, subjects underwent a resting 2D echocardiogram including routine sampling of mitral valve (MV) inflow and LV tissue Doppler imaging as well as a symptom limited exercise treadmill stress test with echocardiographic imaging. Primary endpoints were 1) changes in systolic blood pressure before and after 10 weeks of treatment and 2) changes in exercise capacity as determined by exercise duration and metabolic equivalent (MET) level before and after treatment. Secondary endpoints were changes in exercise hemodynamics and Doppler echocardiographic parameters of LV systolic and diastolic function and quality of life before and after 10 weeks of nebivolol treatment. Subjects completed an EuroQol (EQ-SD) Quality of Life questionnaire which is a standardized measure of health status developed by the EuroQol group as a simple general measure of health at baseline and at conclusion of the 10 week trial period.
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis (new or established) hypertension, defined by serial measurements \>/= 140/90
Evidence of diastolic dysfunction on echocardiography measured by tissue Doppler
You may not be if
Severe bronchospastic disease/ reactive airway disease
